Literature DB >> 22358651

Hybridoma growth in a new generation hollow fibre bioreactor: antibody productivity and consistency.

N Kessler1, G Thomas, L Gerentes, G Delfosse, M Aymard.   

Abstract

This paper analyses the performance of MAbMax(TM)/Tricentric(TM), a new generation hollow fibre bioreactor, for hybridoma growth and antibody productivity, the down stream processing of monoclonal antibody harvests throughout the run and the further control of antibody quality consistency. Handling and process parameters were optimised using a mouse hybridoma, IgG1(K) secretor, and then confirmed with several other hybridomas. Cells were kept at optimal viability during an unusually long period of time and a continuously high production of antibodies was detected over several months. Foetal bovine serum concentration was reduced to 1\% and the effects of weaning of cells from serum were monitored in terms of cell metabolism and antibody productivity. Antibody harvests collected at regular intervals throughout the run (2 to 12 weeks) were purified using affinity chromatography on a recombinant protein A/G matrix and then analysed in terms of antigen binding properties, isoelectric forms and oligosaccharide structures, in order 1) to control antibody quality consistency as a function of time and serum concentration and 2) to compare antibody characteristics as a function of culture conditions, in vitro bioreactor cultivation versus in vivo mouse ascite cultivation.

Entities:  

Year:  1997        PMID: 22358651      PMCID: PMC3449582          DOI: 10.1023/A:1007922004714

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  10 in total

1.  Generation of specificity-variant antibodies by alteration of carbohydrate in light chain of human monoclonal antibodies.

Authors:  H Tachibana; S Shirahata; H Murakami
Journal:  Biochem Biophys Res Commun       Date:  1992-12-15       Impact factor: 3.575

2.  A radial flow hollow fiber bioreactor for the large-scale culture of mammalian cells.

Authors:  J P Tharakan; P C Chau
Journal:  Biotechnol Bioeng       Date:  1986-03       Impact factor: 4.530

3.  Cell culture on artificial capillaries: an approach to tissue growth in vitro.

Authors:  R A Knazek; P M Gullino; P O Kohler; R L Dedrick
Journal:  Science       Date:  1972-10-06       Impact factor: 47.728

4.  Isolation and characterization of electrophoretically homogeneous rabbit antihapten antibody populations. II. A survey of the isoelectric properties of antihapten antibodies directed against charged and uncharged haptens.

Authors:  R H Painter; M H Freedman
Journal:  J Biol Chem       Date:  1971-11       Impact factor: 5.157

5.  The carbohydrate contents of fragments and polypeptide chains of human gamma-G-myeloma proteins of different heavy-chain subclasses.

Authors:  C A Abel; H L Spiegelberg; H M Grey
Journal:  Biochemistry       Date:  1968-04       Impact factor: 3.162

6.  Stability of a murine hybridoma is dependent on the clonal line and culture media.

Authors:  N Kessler; S Bertrand; M Aymard
Journal:  In Vitro Cell Dev Biol       Date:  1993-03

7.  Pilot-scale production of murine monoclonal antibodies in agitated, ceramic-matrix or hollow-fiber cell culture systems.

Authors:  R Kurkela; E Fraune; P Vihko
Journal:  Biotechniques       Date:  1993-10       Impact factor: 1.993

8.  Quality control of murine monoclonal antibodies using isoelectric focusing affinity immunoblot analysis.

Authors:  R G Hamilton; C B Reimer; L S Rodkey
Journal:  Hybridoma       Date:  1987-04

9.  Analysis of glycoforms present in two mouse IgG2a monoclonal antibody preparations.

Authors:  J M Coco-Martin; F Brunink; T A van der Velden-de Groot; E C Beuvery
Journal:  J Immunol Methods       Date:  1992-11-05       Impact factor: 2.303

10.  Different culture methods lead to differences in glycosylation of a murine IgG monoclonal antibody.

Authors:  T P Patel; R B Parekh; B J Moellering; C P Prior
Journal:  Biochem J       Date:  1992-08-01       Impact factor: 3.857

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.